Thus, the ‘biological distance’ between ANGPTL3 and cardiovascular disease may be greater than for LPL and ANGPTL4, suggesting that statistical power may also be lower, even if the relative efficacy of these drug targets might be similar in clinical practice. Here, ANGPTL4 is linked to cardiovascular disorder.